title: Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
abstract: Natural killer (NK) cells are implicated in the regulation of a protective immune response in patients chronically infected with hepatitis C virus (HCV), but effects of interferon-alpha/ribavirin therapy on NK cell subsets and the consequences of viral clearance during therapy remain unclear. Samples were collected from chronically infected patients (n = 34) at baseline and from a subset after 3-10 months on pegylated interferon-alpha and ribavirin therapy (n = 19). NK cells present in cryopreserved PBMC were characterized by flow cytometry. Before therapy, the frequency of CD3-CD56+ NK cells was lower in patients than uninfected controls. Therapy increased proportions of CD56(bright) NK cells. Frequencies of CD56(dim) NK cells declined slightly while perforin and CD16 expression on CD56(dim) NK cells decreased compared to baseline samples. Evaluation of NK cell subsets at baseline did not identify patients able to achieve sustained virological response following therapy. However, therapy may promote the expansion of NK cells able to produce interferon-gamma, while minimizing cytotoxicity to limit liver damage.
authors.affiliation: Department of Microbiology and Infectious Disease, Royal Perth Hospital, Perth, Western Australia, Australia. silvialee@meddent.uwa.edu.au
authors.forename: Silvia
authors.initials: S
authors.lastname: Lee
authors.forename: Mark W
authors.initials: MW
authors.lastname: Watson
authors.forename: James P
authors.initials: JP
authors.lastname: Flexman
authors.forename: Wendy
authors.initials: W
authors.lastname: Cheng
authors.forename: Talia
authors.initials: T
authors.lastname: Hammond
authors.forename: Patricia
authors.initials: P
authors.lastname: Price
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000737:chemistry / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000737:chemistry / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D017252:CD3 Complex; D019002:CD56 Antigen; D016898:Interferon-alpha; D012254:Ribavirin